Amber Implants has received FDA 510(k) clearance for its VCFix Spinal System, a next-generation treatment for vertebral compression fractures (VCFs). The approval confirms the device’s safety and performance and positions the company for a US commercial pilot launch in early 2026, with broader physician availability expected later that year.

The VCFix Spinal System is a minimally invasive vertebral augmentation device designed to treat a broad range of VCFs. It provides both anterior and posterior column support and integrates with existing surgical workflows. The system is intended to improve spinal stability, reduce procedural risk, and shorten recovery times compared with current treatment options.

One-year trial data from initial clinical studies demonstrate significant clinical improvements. Patients experienced immediate and sustained pain reduction, enhanced spinal stability, and faster functional recovery. The device is also being prepared for CE marking in the EU, with plans for a label that supports both stand-alone use and integration with posterior fixation systems.

Dr Banafsheh Sajadi, co-founder and CEO of Amber Implants, said: “The VCFix Spinal System is a groundbreaking vertebral augmentation solution with the potential to establish a new standard of care in vertebral fracture management. The US, as the world’s largest MedTech market, provides an ideal platform for growth with a potential market in excess of €800m, and this clearance lays the foundation to initiate our commercial launch activities.”

Vertebral compression fractures affect more than nine million people globally each year, with around two million cases in North America and Europe. Despite their prevalence, up to two-thirds of cases remain undiagnosed and undertreated, leaving patients—primarily elderly and frail—at risk of chronic pain, spinal deformity, disability, and loss of independence. Current therapies, such as kyphoplasty or posterior fixation, either lack posterior support or are highly invasive, with longer recovery periods. VCFix addresses these limitations by offering minimally invasive dual-column support and improved procedural efficiency.

Dr Mohammad Ahmadi, co-founder and CTO, added: “We will begin our US commercial launch with a pilot program in early 2026, accompanied by expansion of the EXPAND pivotal trial into the US. This will be followed by broader physician availability later in 2026. We continue to pursue EU label expansion for stand-alone use and integration with one-level fixation.”

With FDA clearance and a strong global patent portfolio, Amber Implants aims to capture a significant share of the €2 billion+ global VCF market by 2029, while using US approval as a gateway to other markets where FDA recognition accelerates adoption.